Can you tell me how l-dopa effect the actions of neurotransmitters at the synapse in parkinson's patients?

Explanation: Although Parkinson's is a multi-neurotransmitter deficiency disorder, the main focus involves a dopamine deficiency within the basal ganglia. L-DOPA is a precursor, which is transformed within the body to dopamine after ingestion, and supplements the deficiency present in the substantia nigra which improves communication with areas such as putamen and globus pallidus.